Mariner
SRPT icon

Mariner’s Sarepta Therapeutics SRPT Stock Holding History

Mariner’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.23M Sell
123,922
-95,801
-44% -$1.81M ﹤0.01% 1428
2026
Q1 		$4.78M Sell
219,723
-37,366
-15% -$723K 0.01% 1077
2025
Q4 		$5.53M Buy
257,089
+202,799
+374% +$4.27M 0.01% 963
2025
Q3 		$1.05M Buy
+54,290
New +$968K ﹤0.01% 1872
2025
Q2 		– Sell
-7,459
Closed -$476K – 3676
2025
Q1 		$476K Sell
7,459
-583
-7% -$61.4K ﹤0.01% 2244
2024
Q4 		$978K Buy
8,042
+1,035
+15% +$127K ﹤0.01% 1663
2024
Q3 		$875K Buy
7,007
+163
+2% +$22.5K ﹤0.01% 1719
2024
Q2 		$1.08M Buy
6,844
+613
+10% +$78.7K ﹤0.01% 1453
2024
Q1 		$807K Buy
6,231
+439
+8% +$53.8K ﹤0.01% 1667
2023
Q4 		$559K Buy
5,792
+2,767
+91% +$265K ﹤0.01% 1874
2023
Q3 		$367K Sell
3,025
-192
-6% -$21.7K ﹤0.01% 1988
2023
Q2 		$368K Buy
+3,217
New +$415K ﹤0.01% 1963

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Mariner's SRPT Position: Q2 2026 in Review

Mariner reduced its Sarepta Therapeutics (SRPT) stake by 44% in Q2 2026, selling an estimated $1.81M and leaving 123,922 shares worth $2.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1428.

Mariner first reported a position in SRPT in Q2 2023 and has held it in 12 quarters since. The position peaked at $5.53M in Q4 2025. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Mariner held 123,922 shares of Sarepta Therapeutics worth $2.23M as of Q2 2026.
  • Mariner sold 95,801 Sarepta Therapeutics shares in Q2 2026, an estimated $1.81M.
  • Sarepta Therapeutics made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #1428 holding.
  • Mariner first reported a position in Sarepta Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • Mariner's Sarepta Therapeutics position peaked at $5.53M in Q4 2025.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.